Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension

References

• Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA303(20), 2043–2050 (2010).
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K et al. Worldwide prevalence of hypertension: a systemic review. J. Hypertens.22(1), 11–19 (2004).
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality. Lancet360, 1903–1913 (2002).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension42, 1206–1252 (2003).
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Ninomiya T et al.; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ336(7653), 1121–1123 (2008).
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet351, 1755–1762 (1998).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo–Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet366, 895–906 (2005).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet359, 995–1003 (2002).
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet363, 2022–2031 (2004).
   PubMed Web of Science ®Google Scholar
• Cushman WC, Ford CE, Cutler JA et al. Success and predictors of blood pressure control in diverse north American settings: the Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT). J. Clin. Hypertens.4, 393–404 (2002).
   PubMedGoogle Scholar
• Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens.25, 1105–1187 (2007).
   PubMed Web of Science ®Google Scholar
• Neutel JM. The role of combination therapy in the management of hypertension. Nephrol. Dial. Transplant.21(6), 1469–1473 (2006).
   PubMed Web of Science ®Google Scholar
• Materson BJ, Reda DJ, Cushman WC et al. Single drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N. Engl. J. Med.328(13), 914–921 (1993).
   PubMed Web of Science ®Google Scholar
• Milani RV. Reaching for aggressive blood pressure goals: role of angiotensin receptor blockade in combination therapy. Am. J. Manag. Care11(Suppl. 7), S220–S227 (2005).
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Lacourciere Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension54(1), 32–39 (2009).
   PubMed Web of Science ®Google Scholar
• Oparil S, Melino M, Lee J et al. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin. Ther.32(7), 1252–1269 (2010).
   PubMed Web of Science ®Google Scholar
• Black HR. Triple fixed-dose combination therapy: back to the past. Hypertension54, 19–22 (2009).
   PubMed Web of Science ®Google Scholar
• Gradman A. Rationale for triple-combination therapy for management of high blood pressure. J. Clin. Hypertens.12(11), 869–878 (2010).
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med.359, 2417–2428 (2008).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med.345(23), 1667–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Kober L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N. Engl. J. Med.333(25), 1670–1676 (1995).
   PubMed Web of Science ®Google Scholar
• Pfeffer M, Braunwald E, Moye L. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators. N. Engl. J. Med.325(5), 293–302 (1991).
   PubMedGoogle Scholar
• Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. N. Engl. J. Med.327(10), 669–677 (1992).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation study investigators. N. Engl. J. Med.342(3), 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• Maschio G, Alberti D, Janin G et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med.334(15), 939–945 (1996).
   PubMed Web of Science ®Google Scholar
• Persson F, Rossing P, Reinhard H et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with Type 2 diabetes, hypertension, and albuminuria. Diabetes Care32(10), 1873–1879 (2009).
   PubMed Web of Science ®Google Scholar
• Persson F, Lewis JB, Lewis EJ et al. Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with Type 2 diabetes and nephropathy. Diabetes Care33, 2304–2309 (2010).
   PubMed Web of Science ®Google Scholar
• Gradman AH, Schmieder RE, Lins RL et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation111(8), 1012–1018 (2005).
   PubMed Web of Science ®Google Scholar
• Andersen K, Weinberger MH, Egan B et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J. Hypertens.26(3), 589–599 (2008).
   PubMed Web of Science ®Google Scholar
• Uresin Y, Taylor A, Kilo C et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J. Renin Angiotensin Aldosterone Syst.8(4), 190–198 (2007).
   PubMed Web of Science ®Google Scholar
• Drummond W, Munger MA, Rafique Essop M et al. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J. Clin. Hypertens.9(10), 742–750 (2007).
   PubMedGoogle Scholar
• Black H, Weinberger M, Purkayastha D et al. Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension. J. Clin. Hypertens.13, 571–581 (2011).
   PubMed Web of Science ®Google Scholar
• Basile J, Babazadeh S, Lillestol M et al. Comparison of aliskiren/hydrochlorothiazide combination therapy with hydrochlorothiazide monotherapy in older patients with stage 2 systolic hypertension: results of the ACTION study. J. Clin. Hypertens.13(3), 162–169 (2011).
   Google Scholar
• Black HR, Kribben A, Aguirre Palacios F, Bijarnia M, Laflamme AK, Baschiera F. Aliskiren alone or in combination with hydrochlorothiazide in patients with the lower ranges of stage 2 hypertension: The ACQUIRE randomized double-blind study. J. Clin. Hypertens.12(12), 917–926 (2011).
   Google Scholar
• Geiger H, Barranco E, Gorostidi M et al. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone. J. Clin. Hypertens.11(6), 324–332 (2009).
   PubMed Web of Science ®Google Scholar
• Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J. Am. Soc. Hypertens.4, 42–50 (2010).
   PubMed Web of Science ®Google Scholar
• Venkata C, Ram S. Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension. Expert Rev. Cardiovasc. Ther.9(1), 9–19 (2011).
   PubMedGoogle Scholar
• Barrios V, Escobar C. Valsartan–amlodipine–hydrochlorothiazide: the definitive fixed combination? Expert Rev. Cardiovasc. Ther.8(11), 1609–1618 (2010).
   PubMedGoogle Scholar
• Wood JM, Maibaum J, Rahuel J et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun.308(4), 698–705 (2003).
   PubMed Web of Science ®Google Scholar
• Duggan ST, Chwieduk C, Curran MP. Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension. Drugs70(15), 2011–2049 (2010).
   PubMed Web of Science ®Google Scholar
• Azizi M, Menard J, Bissery A et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II–renin feedback interruption. J. Am. Soc. Nephrol.15, 3126–3133 (2004).
   PubMed Web of Science ®Google Scholar
• Nussberger J, Gradman AH, Schmieder RE et al. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int. J. Clin. Pract.61(9), 1461–1468 (2007).
   PubMed Web of Science ®Google Scholar
• Duarte J, Cooper-DeHoff R. Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev. Cardiovasc. Ther.8(6), 793–802 (2010).
   PubMedGoogle Scholar
• Chrysant SG, Melino M, Karki S et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin. Ther.30, 587–604 (2008).
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Jarugula V, Dieterich HA et al. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin. Pharmacokinet.47(8), 515–531 (2008).
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Jermany J, Yeh CH et al. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasin subjects. Br. J. Clin. Pharmacol.62(6), 690–698 (2006).
   PubMed Web of Science ®Google Scholar
• Buczko W, Hermanowicz JM. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. Pharmacol. Rep.60(5), 623–631 (2008).
   PubMedGoogle Scholar
• Murdoch D, Heel RC. Amlodipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs41(3), 478–505 (1991).
   PubMed Web of Science ®Google Scholar
• Haria M, Wagstaff AJ. Amlodipine: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs50(3), 560–586 (1995).
   PubMed Web of Science ®Google Scholar
• Meredith PA, Elliott HL. Clinical pharmacokinetics of amlodipine. Clin. Pharmacokinet.22, 22–31 (1992).
   PubMed Web of Science ®Google Scholar
• Chrysant SG. Aliskiren–hydrochlorothiazide combination for the treatment of hypertension. Expert Rev.Cardiovasc. Ther.6(3), 305–314 (2008).
   PubMedGoogle Scholar
• Brown MJ, McInnes GT, Papst CC et al. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomized, parallel-group trial. Lancet377, 312–320 (2011).
   PubMed Web of Science ®Google Scholar
• Ferdinand KC, Weitzman R, Israel M et al. Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension. J. Am. Soc. Hypertens.5(2), 102–113 (2011).
   PubMed Web of Science ®Google Scholar
• Richter D, Mickel C, Acharya S et al. Aliskiren-based stepped-care treatment algorithm provides effective blood pressure control. Int. J. Clin. Pract.65(5), 613–623 (2011).
   PubMedGoogle Scholar
• Littlejohn TW 3rd, Trenkwalder P, Hollanders G et al. Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. Curr. Med. Res. Opin.25(4), 951–959 (2009).
   PubMed Web of Science ®Google Scholar
• Schweizer J, Ulmer HJ, Benduhn H et al. Efficacy and tolerability of aliskiren 300mg/hydrochlorothiazide 25mg (± amlodipine 5mg) in hypertensive patients not controlled by candesartan 32mg plus HCT 25mg. Curr. Med. Res. Opin.27(1), 131–140 (2011).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Thijisq L, Fagard R et al.; Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe trial. J. Hypertens.22, 847–857 (2004).
   PubMed Web of Science ®Google Scholar
• Smith TR, Glazer R, Koren MJ et al. Long-term safety and efficacy of combination therapy with amlodipine and valsartan in hypertensive patients. J. Clin. Hypertens.10, A35 (2008) (Abstract P-70).
   Google Scholar
• Villamil A, Chrysant SG, Calhoun D et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J. Hypertens.25(1), 217–226 (2007).
   PubMed Web of Science ®Google Scholar
• Ferdinand K, Pool J, Weitzman R et al. Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST Trial. J. Clin. Hypertens.13(5), 366–375 (2011).
   Web of Science ®Google Scholar
• Stanton AV, Gradman AH, Schmieder RE, Nussberger J, Sarangapani R, Prescott MF. Aliskiren monotherapy does not cause paradoxical blood pressure rises: meta-analysis of data from 8 clinical trials. Hypertension55, 54–60 (2010).
   PubMed Web of Science ®Google Scholar
• Tapaninen T, Neuvonen P, Niemi M. Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. Br. J. Clin. Pharmacol.71(5), 718–726 (2011).
   PubMed Web of Science ®Google Scholar
• Waldmeier F, Glaenzel U, Wirz B et al. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab. Dispos.35, 1418–1428 (2007).
   PubMed Web of Science ®Google Scholar